Core Insights - Abeona Therapeutics Inc. will have its CEO, Vish Seshadri, present at the Leerink Partners Global Healthcare Conference on March 10, 2025 [1] - A live webcast of the presentation will be available on the company's website and archived for 30 days [2] Company Overview - Abeona Therapeutics is a clinical-stage biopharmaceutical company focused on developing cell and gene therapies for serious diseases [3] - The company is working on Prademagene zamikeracel (pz-cel), an investigational autologous, COL7A1 gene-corrected epidermal sheet for recessive dystrophic epidermolysis bullosa [3] - Abeona has a fully integrated cGMP manufacturing facility that supports the production of pz-cel for its Phase 3 VIITAL™ trial and future commercial production upon FDA approval [3] - The company also has AAV-based gene therapies targeting ophthalmic diseases with high unmet medical needs, utilizing next-generation AAV capsids to enhance tropism profiles [3]

Core Insights - Aclaris Therapeutics, Inc. is participating in two healthcare conferences in March 2025, showcasing its focus on immuno-inflammatory diseases [1][5] - The company is a clinical-stage biopharmaceutical firm developing novel product candidates to address unmet needs in immuno-inflammatory diseases [3] Conference Participation - Aclaris' CEO Dr. Neal Walker and senior leadership will engage in a fireside chat at the Leerink Partners Global Healthcare Conference on March 11, 2025, at 3:00 PM EDT [5] - Aclaris will also participate in a virtual fireside chat during the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on March 27, 2025, at 9:00 AM EDT [5] Company Overview - Aclaris Therapeutics is focused on developing a pipeline of product candidates aimed at patients with immuno-inflammatory diseases who currently lack satisfactory treatment options [3] - The company boasts a multi-stage portfolio supported by a robust research and development engine [3]

Company Overview - AC Immune SA is a clinical-stage biopharmaceutical company focused on precision medicine for neurodegenerative diseases, including Alzheimer's and Parkinson's diseases, utilizing misfolded proteins as a target [3] - The company has two clinically validated technology platforms, SupraAntigen and Morphomer, which support a diverse pipeline of sixteen therapeutic and diagnostic programs, with five in Phase 2 and one in Phase 3 development [3] - AC Immune has established strategic partnerships with leading global pharmaceutical companies, resulting in over $4.5 billion in potential milestone payments and royalties [3] Upcoming Events - AC Immune management will participate in the Leerink Partners 2025 Global Healthcare Conference on March 10, 2025, and the Barclays 27th Annual Global Healthcare Conference on March 11, 2025 [6]

As filed with the U.S. Securities and Exchange Commission on October 27, 2023 Registration No. 333-272230 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 THE SECURITIES ACT OF 1933 AIMEI HEALTH TECHNOLOGY CO., LTD (Exact name of registrant as specified in its charter) | Cayman Islands | 6770 | N/A | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer | | incorporation or organization) | Classification Code Number) | Identification N ...

As filed with the U.S. Securities and Exchange Commission on October 27, 2023 Registration No. 333-272230 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 5 TO FORM S-1 THE SECURITIES ACT OF 1933 REGISTRATION STATEMENT UNDER AIMEI HEALTH TECHNOLOGY CO., LTD The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Re ...

As filed with the U.S. Securities and Exchange Commission on August 31, 2023 Registration No. 333-272230 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AIMEI HEALTH TECHNOLOGY CO., LTD (Exact name of registrant as specified in its charter) | Cayman Islands | 6770 | N/A | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer | | incorporation or organi ...

As filed with the U.S. Securities and Exchange Commission on August 31, 2023 Registration No. 333-272230 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AIMEI HEALTH TECHNOLOGY CO., LTD (Exact name of registrant as specified in its charter) | Cayman Islands | 6770 | N/A | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer | | incorporation or organi ...

As filed with the U.S. Securities and Exchange Commission on August 17, 2023 Registration No. 333-272230 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AIMEI HEALTH TECHNOLOGY CO., LTD (Exact name of registrant as specified in its charter) | Cayman Islands | 6770 | N/A | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer | | incorporation or organi ...

As filed with the U.S. Securities and Exchange Commission on August 17, 2023 Registration No. 333-272230 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AIMEI HEALTH TECHNOLOGY CO., LTD (Exact name of registrant as specified in its charter) | Cayman Islands | 6770 | N/A | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer | | incorporation or organi ...

THE SECURITIES ACT OF 1933 AIMEI HEALTH TECHNOLOGY CO., LTD As filed with the U.S. Securities and Exchange Commission on July 21, 2023 Registration No. 333-272230 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER (Exact name of registrant as specified in its charter) | Cayman Islands | 6770 | N/A | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer | | incorporation or organiza ...